Effect of interpregnancy interval after a mifepristone-induced abortion on neonatal outcomes in subsequent pregnancy

Contraception. 2013 Jan;87(1):38-44. doi: 10.1016/j.contraception.2012.08.043. Epub 2012 Oct 4.

Abstract

Background: The study evaluated effects of interpregnancy interval (IPI) on neonatal outcomes after mifepristone-induced abortion in the first pregnancy.

Study design: This observational cohort study, conducted from 1998 to 2001 at antenatal clinics in Shanghai, Beijing, and Chengdu, China, included 4682 nulliparous women with one mifepristone-induced abortion in their first pregnancy, who were enrolled and followed up until delivery. We compared neonatal outcomes among women with different IPIs between their mifepristone-induced abortion and subsequent pregnancy.

Results: When compared to IPI of 18-24 months, there was an increased risk of the neonate being small for gestational age (SGA) [adjusted odds ratio (aOR): 2.01; 95% confidence interval (CI): 1.04-3.88] when IPI was <6 months; this risk was greater among women without a curettage history after abortion (aOR: 2.49; 95% CI: 1.13-5.50). The associations between IPI and preterm delivery (<37 weeks), low birth weight (<2500 g), mean birth weight and ponderal index were not statistically significant.

Conclusions: The results indicate that an IPI <6 months after one mifepristone-induced abortion in first pregnancy is associated with an increased risk of SGA in the subsequent pregnancy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Abortifacient Agents, Steroidal / administration & dosage
  • Abortifacient Agents, Steroidal / adverse effects*
  • Abortion, Induced / adverse effects*
  • Adult
  • Birth Intervals*
  • China / epidemiology
  • Cohort Studies
  • Female
  • Humans
  • Infant, Newborn
  • Infant, Small for Gestational Age*
  • Mifepristone / administration & dosage
  • Mifepristone / adverse effects*
  • Odds Ratio
  • Pregnancy
  • Premature Birth / epidemiology*
  • Time Factors
  • Young Adult

Substances

  • Abortifacient Agents, Steroidal
  • Mifepristone